

STATE OF NEVADA
LEGISLATIVE COUNSEL BUREAU

LEGISLATIVE BUILDING
401 S. CARSON STREET
CARSON CITY, NEVADA 89701-4747
Fax No.: (775) 684-6600



LEGISLATIVE COMMISSION (775) 684-6800
NICOLE J. CANNIZZARO, *Senator, Chair*
Brenda J. Erdoes, *Director, Secretary*

INTERIM FINANCE COMMITTEE (775) 684-6821
MAGGIE CARLTON, *Assemblywoman, Chair*
Cindy Jones, *Fiscal Analyst*
Mark Krmpotic, *Fiscal Analyst*

BRENDA J. ERDOES, *Director*
(775) 684-6800

LEGISLATIVE COUNSEL (775) 684-6830
DANIEL L. CROSSMAN, *Legislative Auditor* (775) 684-6815
MICHAEL J. STEWART, *Research Director* (775) 684-6825

MEETING NOTICE AND AGENDA

Name of Organization: Committee to Conduct an Interim Study Concerning the Costs of Prescription Drugs
([Senate Bill 276 \[2019\]](#))

Date and Time of Meeting: Wednesday, September 9, 2020
9 a.m.

Place of Meeting: Pursuant to Sections 2 through 9, inclusive, of Chapter 2, *Statutes of Nevada 2020*, 32nd Special Session, pages 9 through 11, there will be no physical location for this meeting. The meeting can be listened to or viewed live over the Internet. The address for the Nevada Legislature's website is <http://www.leg.state.nv.us>. Click on the link "[View Meetings & Press Conferences.](#)"

We are pleased to make reasonable accommodations for members of the public with a disability. If accommodations for the meeting are necessary, please notify the Research Division of the Legislative Counsel Bureau, in writing, at research@lcb.state.nv.us, or call the Research Division at (775) 684-6825 as soon as possible.

Minutes of this meeting will be produced in summary format. Please submit electronic copies of testimony and visual presentations if you wish to have complete versions included as exhibits with the minutes to RxDrugs@lcb.state.nv.us. You may also mail written documents to the Research Division, 401 South Carson St., Carson City, NV 89701, or fax them to (775) 684-6600.

Items on this agenda may be taken in a different order than listed. Two or more agenda items may be combined for consideration. An item may be removed from this agenda or discussion relating to an item on this agenda may be delayed at any time.

I. Opening Remarks
Senator Yvanna D. Cancela, Chair

II. Public Comment
Because there is no physical location for this meeting, public testimony under this agenda item may be presented by phone or written comment.
Because of time considerations, each caller offering testimony during this period for public comment will be limited to not more than 3 minutes. To call in to provide testimony during this period of public comment in the meeting any time after 1:00 p.m. on July 28, 2020, dial (669) 900-6833. When prompted to provide the Meeting ID, please enter 910 7160 2656 and then press #. When prompted for a Participant ID, please press #. To resolve any issues related to dialing in to provide public comment for this meeting, please call (775) 684-6990.

A person may also have comments added to the minutes of the meeting by submitting them in writing either in addition to testifying or in lieu of testifying. Written comments may be submitted electronically before, during, or after the meeting by email to RxDrugs@lcb.state.nv.us. You may also mail written documents to the Research Division, 401 South Carson St., Carson City, NV 89701, or fax them to (775) 684-6600.

For Possible Action

III. Approval of the Minutes for the Meeting on July 1, 2020

For Possible Action

IV. Overview of the Impact of the Coronavirus Disease of 2019 on Communities of Color in Nevada
Representative of the Kenny Guinn Center for Policy Priorities

For Possible Action

V. Work Session—Discussion and Possible Action Relating to:

- A. Intra- and Interstate Purchasing Coalitions
- B. Licensure of Pharmaceutical Sales Representatives
- C. Pharmaceutical Drug Pricing Transparency
- D. Pharmacy Benefit Managers

The “Work Session Document” (WSD) contains recommendations proposed at this, the fourth and final meeting, and other meetings of the Committee to Conduct an Interim Study Concerning the Costs of Prescription Drugs during the 2019-2020 Legislative Interim. The [WSD](#) is available on the Committee’s [Meeting Page](#). Contact Patrick B. Ashton, Senior Policy Analyst, Research Division, Legislative Counsel Bureau, at (775) 684-6825 for a written copy.

VI. Public Comment

Because there is no physical location for this meeting, public testimony under this agenda item may be presented by phone or written comment.

Because of time considerations, each caller offering testimony during this period for public comment will be limited to not more than 3 minutes. To provide public testimony by telephone during this period of public comment, members of the public may call any time after the Chair announces this second period of public comment on July 28, 2020. To call in, dial (669) 900-6833. When prompted to provide the Meeting ID, please enter 910 7160 2656 and then press #. When prompted for a Participant ID, please press #. To resolve any issues related to dialing in to provide public comment for this meeting, please call (775) 684-6990.

A person may also have comments added to the minutes of the meeting by submitting them in writing either in addition to testifying or in lieu of testifying. Written comments may be submitted electronically before, during, or after the meeting by email to RxDrugs@lcb.state.nv.us. You may also mail written documents to the Research Division, 401 South Carson St., Carson City, NV 89701, or fax them to (775) 684-6600.

VII. Adjournment

Notice of this meeting was posted on the Internet through the Nevada Legislature’s website at www.leg.state.nv.us. Supporting public material provided to Committee members for this meeting may be requested from Crystal Rowe, Research Policy Assistant, Research Division, Legislative Counsel Bureau, at (775) 684-6825 or by email at RxDrugs@lcb.state.nv.us and is/will be available at the Nevada Legislature’s website at www.leg.state.nv.us.